Skip to main content
Top

01-09-2016 | Axial spondyloarthritis | Article

Prevalence of peripheral and extra-articular disease in ankylosing spondylitis versus non-radiographic axial spondyloarthritis: a meta-analysis

Journal: Arthritis Research & Therapy

Authors: Janneke J. de Winter, Leonieke J. van Mens, Désirée van der Heijde, Robert Landewé, Dominique L. Baeten

Publisher: BioMed Central

Abstract

Background

Peripheral disease (arthritis, enthesitis and dactylitis) and extra-articular disease (uveitis, psoriasis and inflammatory bowel disease) is common in ankylosing spondylitis (AS) and non-radiographic axial spondyloarthritis (nr-axSpA). So far, however, summary data on the prevalence are lacking. The objective of this meta-analysis was to assess the prevalence of peripheral and extra-articular manifestations in ankylosing spondylitis (AS) and nr-axSpA.

Methods

We performed a systematic literature search to identify publications describing the prevalence of peripheral and extra-articular disease manifestations in patients with AS and nr-axSpA. We assessed the risk of bias and between-study heterogeneity, and extracted data. Pooled prevalence and prevalence differences were calculated.

Results

Eight studies comprising 2236 patients with AS and 1242 with nr-axSpA were included: 7 of the studies were longitudinal cohort studies. There was male predominance in AS (70.4 %, 95 % CI 64.4, 76.0 %) but not in nr-axSpA (46.8 %, 95 % CI 41.7, 51.9), which was independent of the prevalence of human leukocyte antigen (HLA)-B27. The prevalence of HLA-B27 was similar in AS (78.0 % (95 % CI 73.9, 81.9 %) and nr-axSpA (77.4 %, 95 % CI 68.9, 84.9 %)). The pooled prevalence of arthritis (29.7 % (95 % CI 22.4, 37.4 %) versus 27.9 % (95 % CI 16.0, 41.6 %)), enthesitis (28.8 % (95 % CI 2.6, 64.8) versus 35.4 % (95 % CI 6.1, 71.2)). dactylitis (6.0 % (95 % CI 4.7, 7.5 %) versus 6.0 % (95 % CI 1.9, 12.0 %)), psoriasis (10.2 % (95 % CI 7.5, 13.2 %) versus 10.9 % (95 % CI 9.1, 13.0 %)) and inflammatory bowel disease (4.1 % (95 % CI 2.3, 6.5 %) versus 6.4 % (95 % CI 3.6, 9.7 %)) were similar in AS and nr-axSpA. The pooled prevalence of uveitis was higher in AS (23.0 % (95 % CI 19.2, 27.1 %)) than in nr-axSpA (15.9 % (95 % CI 11.8, 20.4 %)).

Conclusion

Peripheral and extra-articular manifestations are equally prevalent in AS and nr-axSpA, except for uveitis, which is slightly more prevalent in AS. These data provide evidence for the largely equal nature of disease manifestations in nr-axSpA and AS.
Literature
1.
Dougados M, Baeten D. Spondyloarthritis. Lancet. 2011;377:2127–37.CrossRefPubMed
2.
Reveille JD, Witter JP, Weisman MH. Prevalence of axial spondylarthritis in the United States: estimates from a cross-sectional survey. Arthritis Care Res (Hoboken). 2012;64:905–10.CrossRef
3.
Rudwaleit M, Landewé R, van der Heijde D, Listing J, Brandt J, Braun J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. Ann Rheum Dis. 2009;68:770–6.CrossRefPubMed
4.
Rudwaleit M, van der Heijde D, Landewé R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis. 2009;68:777–83.CrossRefPubMed
5.
Rudwaleit M, van der Heijde D, Landewé R, Akkoc N, Brandt J, Chou CT, et al. The Assessment of SpondyloArthritis International Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis. 2011;70:25–31.CrossRefPubMed
6.
Wallis D, Haroon N, Ayearst R, Carty A, Inman RD. Ankylosing spondylitis and nonradiographic axial spondyloarthritis: part of a common spectrum or distinct diseases? J Rheumatol. 2013;40:2038–41.CrossRefPubMed
7.
Robinson PC, Wordsworth BP, Reveille JD, Brown M. Axial spondyloarthritis: a new disease entity, not necessarily early ankylosing spondylitis. Ann Rheum Dis. 2013;72:162–4.CrossRefPubMed
8.
Huerta-Sil G, Casasola-Vargas JC, Londono JD, Rivas-Ruiz R, Chavez J, Pacheco-Tena C, et al. Low grade radiographic sacroiliitis as prognostic factor in patients with undifferentiated spondyloarthritis fulfilling diagnostic criteria for ankylosing spondylitis throughout follow up. Ann Rheum Dis. 2006;65:642–6.CrossRefPubMed
9.
Ciurea A, Scherer A, Exer P, Bernhard JJ, Dudler J, Beyeler B, et al. Tumor necrosis factor alpha inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort. Arthritis Rheum. 2013;65:3096–106.CrossRefPubMed
10.
Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. Do patients with non-radiographic axial spondylarthritis differ from patients with ankylosing spondylitis? Arthritis Care Res (Hoboken). 2012;64:1415–22.CrossRef
11.
Rudwaleit M, Haibel H, Baraliakos X, Listing J, Märker-Hermann E, Zeidler H, et al. The early disease stage in axial spondylarthritis: results from the GErman SPondyloarthritis Inception Cohort. Arthritis Rheum. 2009;60:717–27.CrossRefPubMed
12.
Baeten D, Breban M, Lories R, Schett G, Sieper J. Are spondylarthritides related but distinct conditions or a single disease with a heterogeneous phenotype? Arthritis Rheum. 2013;65:12–20.CrossRefPubMed
13.
Rudwaleit M, Khan MA, Sieper J. Commentary: The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? Arthritis Rheum. 2005;52:1000–8.CrossRefPubMed
14.
Poddubnyy D, Haibel H. Clinical course over two years in patients with early non-radiographic axial spondyloarthritis and ankylosing spondylitis without anti-tumour necrosis factor α treatment: results from the GErman SPondyloarthritis Inception Cohort (GESPIC). Arthritis Rheumatol. 2015;67:2369–75.CrossRefPubMed
15.
Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown M a, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2012;72:815–822.
16.
Song I-H, Weiß A, Hermann K-G a, Haibel H, Althoff CE, Poddubnyy D, et al. Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. Ann Rheum Dis. 2013;72:823–5.CrossRefPubMed
17.
Callhoff J, Sieper J, Weiß A, Zink A, Listing J. Efficacy of TNFα blockers in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis. Ann Rheum Dis. 2015;74:1241–8.
18.
McCormick D, McKnight J, Pendleton a. Anti-TNF response rates in radiographic and non-radiographic axial spondyloarthropathy. Ann Rheum Dis. 2014;74:e21.CrossRefPubMed
19.
van den Berg R, Lenczner G, Feydy A, van der Heijde D, Reijnierse M, Saraux A, et al. Agreement between clinical practice and trained central reading in reading of sacroiliac joints on plain pelvic radiographs: results from the DESIR cohort. Arthritis Rheumatol. 2014;66:2403–11.CrossRefPubMed
20.
van Tubergen a, Heuft-Dorenbosch L, Schulpen G, Landewé R, Wijers R, van der Heijde D, et al. Radiographic assessment of sacroiliitis by radiologists and rheumatologists: does training improve quality? Ann Rheum Dis. 2003;62:519–25.CrossRefPubMedPubMedCentral
21.
Sieper J, van der Heijde D, Dougados M, Mease PJ, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis. 2013;72:815–22.CrossRefPubMed
22.
Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum. 2008;58:1981–91.CrossRefPubMed
23.
van den Berg R, de Hooge M, van Gaalen F, Reijnierse M, Huizinga T, van der Heijde D. Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the SPondyloArthritis Caught Early (SPACE) cohort. Rheumatology (Oxford). 2013;52:1492–9.CrossRef
24.
Kiltz U, Baraliakos X, Karakostas P, Igelmann M, Kalthoff L, Klink C, et al. The degree of spinal inflammation is similar in patients with axial spondyloarthritis who report high or low levels of disease activity: a cohort study. Ann Rheum Dis. 2012;71:1207–11.CrossRef
25.
Vander Cruyssen B, Ribbens C, Boonen A, Mielants H, de Vlam K, Lenaerts J, et al. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice. Ann Rheum Dis. 2007;66:1072–7.CrossRefPubMed
26.
Paramarta JE, De Rycke L, Ambarus CA, Tak PP, Baeten D. Undifferentiated spondyloarthritis vs ankylosing spondylitis and psoriatic arthritis: a real-life prospective cohort study of clinical presentation and response to treatment. Rheumatology (Oxford). 2013;52:1873–8.CrossRef
27.
Heuft-Dorenbosch L, van Tubergen A, Spoorenberg A, Landewé R, Dougados M, Mielants H, et al. The influence of peripheral arthritis on disease activity in ankylosing spondylitis patients as measured with the Bath Ankylosing Spondylitis Disease Activity Index. Arthritis Rheum. 2004;51:154–9.CrossRefPubMed
28.
Pérez Alamino R, Maldonado Cocco J a, Citera G, Arturi P, Vazquez-Mellado J, Sampaio-Barros PD, et al. Differential features between primary ankylosing spondylitis and spondylitis associated with psoriasis and inflammatory bowel disease. J Rheumatol. 2011;38:1656–60.CrossRefPubMed
29.
Zeboulon N, Dougados M, Gossec L. Prevalence and characteristics of uveitis in the spondyloarthropathies: a systematic literature review. Ann Rheum Dis. 2008;67:955–9.CrossRefPubMed
30.
Stolwijk C, van Tubergen A, Castillo-Ortiz JD, Boonen A. Prevalence of extra-articular manifestations in patients with ankylosing spondylitis: a systematic review and meta-analysis. Ann Rheum Dis. 2013;74:65–73.
31.
Exarchou S, Redlund-Johnell I, Karlsson M, Mellstrom D, Ohlsson C, Turesson C, et al. The prevalence of moderate to severe radiographic sacroiliitis and the correlation with health status in elderly Swedish men–the MrOS study. BMC Musculoskelet Disord. 2013;14:352.CrossRefPubMedPubMedCentral
32.
Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol. 2006;20:451–71.CrossRefPubMed
33.
Essers I, Ramiro S, Stolwijk C, Blaauw M, Landewé R, van der Heijde D, et al. Characteristics associated with the presence and development of extra-articular manifestations in ankylosing spondylitis: 12-year results from OASIS. Rheumatology (Oxford). 2014;54:633–40.
34.
Stolwijk C, Essers I, van Tubergen A, Boonen A, Bazelier MT, De Bruin ML, et al. The epidemiology of extra-articular manifestations in ankylosing spondylitis: a population-based matched cohort study. Ann Rheum Dis. 2014;74:1373–8.
35.
Schlosser RW, Wendt O, Bhavnani S, Nail-Chiwetalu B. Use of information-seeking strategies for developing systematic reviews and engaging in evidence-based practice: the application of traditional and comprehensive Pearl Growing. A review. Int J Lang Commun Disord. 2006;41:567–82.CrossRefPubMed
36.
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic reviews and Meta-Analyses: the PRISMA statement. J Clin Epidemiol. 2009;62:1006–12.CrossRefPubMed
37.
Dougados M, Van der Linden S, Juhlin R, Huitfeldt B, Amor B, Calin A, et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum. 1991;34:1218–27.CrossRefPubMed
38.
Van der Linden S, Valkenburg H, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheumatol. 1984;27:361–8.CrossRef
39.
Shamliyan T a, Kane RL, Ansari MT, Raman G, Berkman ND, Grant M, et al. Development quality criteria to evaluate nontherapeutic studies of incidence, prevalence, or risk factors of chronic diseases: pilot study of new checklists. J Clin Epidemiol. 2011;64:637–57.CrossRefPubMed
40.
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327:557–60.CrossRefPubMedPubMedCentral
41.
Borenstein M, Hedges L, Higgins J, Rothstein H. Introduction to meta-analysis. 2009.
42.
Barendregt JJ, Doi S a, Lee YY, Norman RE, Vos T. Meta-analysis of prevalence. J Epidemiol Community Health. 2013;67:974–8.CrossRefPubMed
43.
Blachier M, Canouï-Poitrine F, Dougados M, Lethuaut A, Fautrel B, Ferkal S, et al. Factors associated with radiographic lesions in early axial spondyloarthritis. Results from the DESIR cohort. Rheumatology (Oxford). 2013;52:1686–93.CrossRef
44.
Hernández-sanz A, Fernández-carballido VNC, Montilla-morales C, Mulero-mendoza J, de Miguel E. Ankylosing spondylitis and non-radiographic spondyloarthritis: the same syndrome or different diseases? Analyses from Esperanza cohort. In: ACR annual meeting; 2014: Abstract number: 2604.
45.
Kilic E, Kilic G, Akgul O, Ozgocmen S. Discriminant validity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) in patients with non-radiographic axial spondyloarthritis and ankylosing spondylitis: a cohort study. Rheumatol Int. 2014;35:981–989.
46.
Resnick D, Dwosh IL, Goergen TG, Shapiro RF, Utsinger PD, Wiesner KB, et al. Clinical and radiographic abnormalities in ankylosing spondylitis: a comparison of men and women. Radiology. 1976;119:293–7.CrossRefPubMed
47.
Gran JT, Husby G, Hordvik M, Stormer J, Romberg-Andersen O. Radiological changes in men and women with ankylosing spondylitis. Ann Rheum Dis. 1984;43:570–5.CrossRefPubMedPubMedCentral
48.
Boyer GS, Templin DW, Bowler A, Lawrence RC, Heyse SP, Everett DF, et al. Spondyloarthropathy in the community: differences in severity and disease expression in Alaskan Eskimo men and women. J Rheumatol. 2000;27:170–6.PubMed